Market Momentum: Caribou Biosciences Inc (CRBU) Registers a -1.33% Decrease, Closing at $2.23

Kevin Freeman

Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.

Caribou Biosciences Inc (NASDAQ: CRBU) closed the day trading at $2.23 down -1.33% from the previous closing price of $2.26. In other words, the price has decreased by -$1.33 from its previous closing price. On the day, 1.39 million shares were traded. CRBU stock price reached its highest trading level at $2.36 during the session, while it also had its lowest trading level at $2.17.

Ratios:

For a better understanding of CRBU, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.66 and its Current Ratio is at 6.66. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.14.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for the company, Evercore ISI on June 03, 2024, Downgraded its rating to In-line and sets its target price to $3 from $13 previously.

On October 31, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $13.Evercore ISI initiated its Outperform rating on October 31, 2023, with a $13 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 14 ’25 when Haurwitz Rachel E. bought 20,000 shares for $1.02 per share. The transaction valued at 20,400 led to the insider holds 3,369,395 shares of the business.

MCCLUNG BARBARA G sold 3,564 shares of CRBU for $4,811 on Feb 21 ’25. The Chief Legal Officer now owns 443,502 shares after completing the transaction at $1.35 per share. On Feb 21 ’25, another insider, Khan Ruhi Ahmad, who serves as the Chief Business Officer of the company, sold 3,564 shares for $1.35 each. As a result, the insider received 4,811 and left with 66,936 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRBU now has a Market Capitalization of 207664832 and an Enterprise Value of 49567824. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.77 while its Price-to-Book (P/B) ratio in mrq is 1.25. Its current Enterprise Value per Revenue stands at 5.434 whereas that against EBITDA is -0.339.

Stock Price History:

The Beta on a monthly basis for CRBU is 2.59, which has changed by 0.19251335 over the last 52 weeks, in comparison to a change of 0.16766965 over the same period for the S&P500. Over the past 52 weeks, CRBU has reached a high of $3.00, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 14.63%, while the 200-Day Moving Average is calculated to be 56.24%.

Shares Statistics:

Over the past 3-months, CRBU traded about 1.30M shares per day on average, while over the past 10 days, CRBU traded about 1415200 shares per day. A total of 93.12M shares are outstanding, with a floating share count of 82.13M. Insiders hold about 11.80% of the company’s shares, while institutions hold 40.84% stake in the company. Shares short for CRBU as of 1757894400 were 4112720 with a Short Ratio of 3.15, compared to 1755216000 on 3889653. Therefore, it implies a Short% of Shares Outstanding of 4112720 and a Short% of Float of 4.63.

Earnings Estimates

. The current rating of Caribou Biosciences Inc (CRBU) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.29 and low estimates of -$0.41.

Analysts are recommending an EPS of between -$1.64 and -$1.64 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$1.71, with 1.0 analysts recommending between -$1.71 and -$1.71.

Revenue Estimates

A total of 7 analysts have provided revenue estimates for CRBU’s current fiscal year. The highest revenue estimate was $14M, while the lowest revenue estimate was $5M, resulting in an average revenue estimate of $9.85M. In the same quarter a year ago, actual revenue was $9.99M

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.